| [1] |
McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma[J]. Hepatology, 2021, 73 Suppl 1(Suppl 1): 4-13.
|
| [2] |
Zheng Y, Zhu M, Li M. Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2020, 146(10): 2439-2446.
|
| [3] |
中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2022年版)[J/OL]. 肿瘤综合治疗电子杂志, 2022, 8(2): 16-53.
|
| [4] |
中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版)[J]. 传染病信息, 2017, 30(3): 111-127.
|
| [5] |
European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012, 56(4): 908-943.
|
| [6] |
Wong RJ, Ahmed A, Gish RG. Elevated alpha-fetoprotein: differential diagnosis-hepatocellular carcinoma and other disorders [J]. Clin Liver Dis, 2015, 19(2): 309-23.
|
| [7] |
Reig M, Forner A, Rimola J. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update[J]. J Hepatol, 2022, 76(3): 681-693.
|
| [8] |
Li W, Liu K, Chen Y, Zhu M, et al. Role of Alpha-Fetoprotein in Hepatocellular Carcinoma Drug Resistance[J]. Curr Med Chem, 2021, 28(6): 1126-1142.
|
| [9] |
Guo C, Liang H, Yuan W, et al. Analysis on the value of soluble intercellular adhesion molecule-1(sICAM-1), alpha fetoprotein (AFP), and aspartate aminotransferase/platelet ratio index(APRI) in predicting the prognostic survival of patients with primary liver cancer after radiofrequency ablation[J]. Ann Palliat Med, 2021, 10(4): 4760-4767.
|
| [10] |
龚培贤, 孙涛, 刘金玮, 等. 肝细胞癌根治性切除术患者术前血清AFP、VEGF水平及肿瘤组织Ki-67表达水平与早期复发的关系[J]. 山东医药, 2022, 62(15): 28-32.
|
| [11] |
Wang X, Wang Q. Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity[J]. Can J Gastroenterol Hepatol, 2018, 2018: 9049252.
|
| [12] |
Yang X, Chen L, Liang Y, et al. Knockdown of alpha-fetoprotein expression inhibits HepG2 cell growth and induces apoptosis[J]. J Cancer Res Ther, 2018, 14(Supplement): S634-S643.
|
| [13] |
Zhu W, Peng Y, Wang L, et al. Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy[J]. Hepatology, 2018, 68(2): 574-589.
|
| [14] |
Li H, Liu Y, Jiang W, et al. Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma[J]. BMC Cancer, 2021, 21(1): 318.
|
| [15] |
Tang W, Miki K, Kokudo N, et al. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma[J]. Int J Oncol, 2003, 22(5): 969-975.
|
| [16] |
Suzuki M, Shiraha H, Fujikawa T, et al. Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma[J]. J Biol Chem, 2005, 280(8): 6409-6415.
|
| [17] |
Yue P, Gao ZH, Xue X, et al. Des-γ-carboxyl prothrombin induces matrix metalloproteinase activity in hepatocellular carcinoma cells by involving the ERK1/2 MAPK signalling pathway[J]. Eur J Cancer, 2011, 47(7): 1115-1124.
|
| [18] |
Gao FJ, Cui SX, Chen MH, et al. Des-gamma-carboxy prothrombin increases the expression of angiogenic factors in human hepatocellular carcinoma cells[J]. Life Sci, 2008, 83(23/24): 815-820.
|
| [19] |
Cui SX, Yu XF, Qu XJ. Roles and Signaling Pathways of Des-γ-Carboxyprothrombin in the Progression of Hepatocellular Carcinoma[J]. Cancer Invest, 2016, 34(9): 459-464.
|
| [20] |
Durazo FA, Blatt LM, Corey WG, et al. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2008, 23(10): 1541-1548.
|
| [21] |
Bertino G, Ardiri A, Malaguarnera M, et al. Hepatocellualar carcinoma serum markers[J]. Semin Oncol, 2012, 39: 410-433.
|
| [22] |
Debes JD, Romagnoli PA, Prieto J, et al. Serum biomarkers for the prediction of hepatocellular carcinoma[J]. Cancers, 2021, 13: 1681.
|
| [23] |
Choi JY, Jung SW, Kim HY, et al. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP[J]. World J Gastroenterol, 2013, 19(3): 339-346.
|
| [24] |
Harimoto N, Yoshida Y, Kurihara T, et al. Prognostic impact of des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma[J]. Transplant Proc, 2015, 47(3): 703-704.
|
| [25] |
Kudo A, Shinoda M, Ariizumi S, et al. Association for Clinical Research on Surgery Group. Des-gamma-carboxy prothrombin affects the survival of HCC patients with marginal liver function and curative treatment: ACRoS1402[J]. J Cancer Res Clin Oncol, 2020, 146(11): 2949-2956.
|
| [26] |
Tateishi R, Shiina S, Yoshida H, et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers[J]. Hepatology, 2006, 44(6): 1518-1527.
|
| [27] |
Yue P, Gao ZH, Xue X, et al. Des-γ-carboxyl prothrombin induces matrix metalloproteinase activity in hepatocellular carcinoma cells by involving the ERK1/2 MAPK signalling pathway[J]. Eur J Cancer, 2011, 47(7): 1115-1124.
|
| [28] |
Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma[J]. Clin Chim Acta, 2001, 313(1/2): 15-19.
|
| [29] |
Taketa K, Okada S, Win N, et al. Evaluation of tumor markers for the detection of hepatocellular carcinoma in Yangon General Hospital, Myanmar[J]. Acta Med Okayama, 2002, 56: 317-320.
|
| [30] |
Khien VV, Mao HV, Chinh TT, et al. Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carci-noma[J]. Int J Biol Markers 2001, 16: 105-111.
|
| [31] |
Zhou JM, Wang T, Zhang KH. AFP-L3 for the diagnosis of early hepatocellular carcinoma: A meta-analysis[J]. Medicine(Baltimore), 2021, 100(43): e27673.
|
| [32] |
Wang X, Zhang Y, Yang N, et al. Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis[J]. Biomed Res Int, 2020, 2020: 5087643.
|
| [33] |
Lim TS, Kim DY, Han KH, et al. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients[J]. Scand J Gastroenterol, 2016, 51(3): 344-353.
|
| [34] |
Singal AG, Tayob N, Mehta A, et al. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis[J]. Hepatology, 2022, 75(3): 541-549.
|
| [35] |
Best J, Bilgi H, Heider D, et al. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma. Der GALAD-Score, ein AFP-, AFP-L3- und DCP-basierter Diagnosealgorithmus verbessert die Detektionsrate des hepatozellulären Karzinoms im BCLC-Frühstadium signifikant[J]. Z Gastroenterol, 2016, 54(12): 1296-1305.
|
| [36] |
Schotten C, Ostertag B, Sowa JP, et al. GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients[J]. Pharmaceuticals(Basel), 2021, 14(8): 735.
|
| [37] |
Sachan A, Kushwah S, Duseja A. GALAD Score for HCC Screening and Surveillance[J]. Clin Gastroenterol Hepatol, 2023, 21(2): 556-557.
|
| [38] |
Yang JD, Addissie BD, Mara KC, et al. GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score[J]. Cancer Epidemiol Biomarkers Prev, 2019, 28(3): 531-538.
|
| [39] |
Ray SK, Mukherjee S. Cell Free DNA as an Evolving Liquid Biopsy Biomarker for Initial Diagnosis and Therapeutic Nursing in Cancer- An Evolving Aspect in Medical Biotechnology[J]. Curr Pharm Biotechnol, 2022, 23(1): 112-122.
|
| [40] |
Udomruk S, Orrapin S, Pruksakorn D, et al. Size distribution of cell-free DNA in oncology[J]. Crit Rev Oncol Hematol, 2021, 166: 103455.
|
| [41] |
Wu X, Li J, Gassa A, et al. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma[J]. Int J Biol Sci, 2020, 16(9): 1551-1562.
|
| [42] |
Howell J, Atkinson SR, Pinato DJ, et al. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma[J]. Eur J Cancer, 2019, 116: 56-66.
|
| [43] |
Matsumae T, Kodama T, Myojin Y, et al. Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy[J]. Cancers(Basel), 2022, 14(14): 3367.
|
| [44] |
Alunni-Fabbroni M, Rönsch K, Huber T, et al. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial[J]. J Transl Med, 2019, 17(1): 328.
|
| [45] |
Oh CR, Kong SY, Im HS, et al. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib[J]. BMC Cancer, 2019, 19(1): 292.
|
| [46] |
Wang Y, Zhou K, Wang X, et al. Multiple-level copy number variations in cell-free DNA for prognostic prediction of HCC with radical treatments[J]. Cancer Sci, 2021, 112(11): 4772-4784.
|
| [47] |
Mao Y, Yang H, Xu H, et al. Golgi protein 73(GOLPH2) is a valuable serum marker for hepatocellular carcinoma[J]. Gut, 2010, 59(12): 1687-1693.
|
| [48] |
Zhang YL, Zhang YC, Han W, et al. Effect of GP73 silencing on proliferation and apoptosis in hepatocellular cancer[J]. World J Gastroenterol, 2014, 20(32): 11287-11296.
|
| [49] |
Zhao J, Xu T, Wang F, Cai W, Chen L. miR-493-5p suppresses hepatocellular carcinoma cell proliferation through targeting GP73[J]. Biomed Pharmacother, 2017, 90: 744-751.
|
| [50] |
Chen X, Wang Y, Tao J, et al. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice[J]. Gastroenterology, 2015, 149(3): 741-52. e14.
|
| [51] |
Wang C, Gao D, Guo K, et al. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model[J]. BMC Cancer, 2012, 12: 166.
|
| [52] |
Uede T. Osteopontin, intrinsic tissue regulator of intractable inflammatory diseases[J]. Pathol Int, 2011, 61(5): 265-280.
|
| [53] |
Pan HW, Ou YH, Peng SY, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma[J]. Cancer, 2003, 98(1): 119-127.
|
| [54] |
Liang KH, Yeh CT. OPN sesame[J]. Hepatobiliary Surg Nutr, 2014, 3(3): 112-114.
|
| [55] |
Lee YJ, Jang BK. Can combination of osteopontin and peritumor-infiltrating macrophages be a prognostic marker of early-stage hepatocellular carcinoma?[J]. Hepatobiliary Surg Nutr, 2014, 3(2): 57-59.
|
| [56] |
Zhou C, Zhou HJ, Zhang XF, et al. Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma[J]. Ann Surg Oncol, 2013, 20(3): 929-937.
|
| [57] |
Zhu Y, Yang J, Xu D, et al. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade[J]. Gut, 2019, 68(9): 1653-1666.
|
| [58] |
Zhu Y, Gao XM, Yang J, et al. C-C chemokine receptor type 1 mediates osteopontin-promoted metastasis in hepatocellular carcinoma[J]. Cancer Sci, 2018, 109(3): 710-723.
|
| [59] |
Chen RX, Xia YH, Xue TC, et al. Transcription factor c-Myb promotes the invasion of hepatocellular carcinoma cells via increasing osteopontin expression[J]. J Exp Clin Cancer Res, 2010, 29(1): 172.
|
| [60] |
Chen RX, Xia YH, Xue TC, et al. Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA. Oncol Rep, 2011, 25(3): 803-808.
|
| [61] |
Iglesias BV, Centeno G, Pascuccelli H, et al. Expression pattern of glypican-3(GPC3) during human embryonic and fetal development[J]. Histol Histopathol, 2008, 23(11): 1333-1340.
|
| [62] |
Capurro M, Wanless IR, Sherman M, et al. Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma[J]. Gastroenterology, 2003, 125(1): 89-97.
|
| [63] |
Zhou F, Shang W, Yu X, et al. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment[J]. Med Res Rev, 2018, 38(2): 741-767.
|